Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data BIOTRICITY INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
0.4
1.42
3.38
7.65
9.64
12.1
13.8
16
Cost of revenue
0.34
0.93
2.11
3.08
4.2
3.71
3.23
3.05
Gross profit
0.06
0.49
1.27
4.57
5.44
8.36
10.6
12.9
Research and development
1.14
1.76
1.31
1.36
2.06
2.74
3.23
2.57
2.16
2.76
Selling, general and administrative
18.6
17.6
14.6
10.9
8.49
General and administrative
4.8
5.96
7.34
10.1
12.6
19.8
Operating expenses
5.94
7.72
8.65
11.4
14.6
21.3
20.9
17.2
13
11.3
Operating income
-16.7
-15.4
-8.83
-2.45
1.69
Interest expense
0.15
1.28
1.84
3.02
3.26
3.36
Other non-operating income
-0.02
0.04
0.02
-0.11
-0.1
-0.08
0.16
Pre-tax income
-8.62
-8.59
-11.1
-15.5
-29.1
-18.7
-14.1
-8.42
-2.4
Net income
-7.81
-8.62
-8.59
-11.1
-15.5
-29.1
-18.7
-14.1
-8.42
-2.4
EBITDA
-16.7
-15.4
-8.82
-2.44
1.7
EPS, basic
-1.81
-1.72
-1.54
-1.89
-2.63
-3.99
-2.26
-1.66
-0.56
-0.12
EPS, diluted
-1.81
-1.72
-1.54
-1.89
-2.63
-3.99
-2.26
-1.66
-0.56
-0.12
Shares, basic (weighted)
4.31
5.03
5.56
5.99
6.25
7.57
8.66
8.99
21.5
27.3
Shares, diluted (weighted)
4.31
5.03
5.56
5.99
6.25
7.57
8.66
8.99
21.5
27.3
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
0.42
0.84
0.06
0.95
2.2
12.1
0.57
0.79
0.37
0.15
Receivables
0.21
0.49
1.52
2.01
1.22
1.47
1.66
2.93
Inventory
0.02
0.09
0.27
0.84
2.34
1.88
1.56
1.34
Total current assets
0.44
0.9
0.46
1.66
4.32
15.3
4.72
4.47
4.64
5.86
Property, plant and equipment
0.02
0.02
0.02
0.01
0
Lease right-of-use assets
0.26
0.07
1.24
1.59
1.22
0.81
0.35
Total assets
0.47
0.93
0.49
2
4.44
16.7
6.51
5.94
5.64
6.45
Accounts payable
0.87
0.55
0.88
1.09
1.04
2.6
5.04
9.61
7.66
8.97
Accrued liabilities
0.27
0.21
0.52
0.43
1.48
1.44
1.61
4.37
3.03
4.53
Total current liabilities
2.27
3.8
10.5
4.87
11.2
22.7
20.6
37.1
Lease liabilities
0.06
1.12
1.39
0.93
0.4
Total liabilities
4.86
0.76
2.27
5
11.3
18.8
26.4
35.9
35.7
39.4
Paid-in capital
14.3
27.2
33.9
44
56.3
91.5
92.8
95.7
107
108
Retained earnings
-18.3
-26.4
-35
-46.4
-62.8
-93
-113
-127
-139
-143
Other comprehensive income
-0.41
-0.64
-0.75
-0.86
-0.63
-0.77
-0.15
0.03
-0.01
-0.04
Shareholders' equity
-4.38
0.17
-1.78
-3
-6.83
-2.14
-19.8
-31.5
-32
-34.7
Total equity
-4.38
0.17
-1.78
-3
-6.83
-2.14
-19.8
-31.5
-32
-34.7
Total liabilities and equity
0.47
0.93
0.49
2
4.44
16.7
6.51
5.94
5.64
6.45
Shares outstanding
3.01
3.95
5.17
5.43
6.02
8.3
8.51
9.35
26.1
28.6
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-7.81
-8.62
-8.59
-11.1
-15.5
-29.1
-18.7
-14.1
-8.42
-2.4
Depreciation and amortization
0.09
2.48
0
0.01
0.01
0.01
0.01
Stock-based compensation
0.63
1
1.45
2.41
0.79
0.91
0.65
1.03
1.46
0.03
Change in receivables
-0.21
-0.33
-1.04
-0.44
0.69
-0.3
-0.11
-1.33
Change in inventory
-0.02
-0.06
-0.19
-0.57
-1.49
0.46
0.32
0.21
Change in payables
-0.39
-0.4
0.65
0.08
0.75
0.95
3.34
3.27
1.5
0.2
Cash from operations
-3.75
-4.87
-5.22
-7.86
-11.1
-15.2
-13.5
-6.69
-2.38
-0.72
Capital expenditures
-0.03
Cash from investing
-0.03
Debt issued
11.8
Debt repaid
-0.44
Stock issued
4.86
3.64
0.03
0.25
0.12
0.13
Dividends paid
-0.18
-0.6
Cash from financing
3.97
5.29
4.56
8.88
12.2
25.2
2
6.74
1.93
0.56
Exchange rate effect
0.17
0.03
-0.05
Net change in cash
0.41
-0.66
1.02
1.19
9.98
-11.5
0.05
-0.45
-0.16
Free cash flow
-15.2
Interest paid
0.02
0.34
0.2
0.55
1.62
2.02
3.61
2.88
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.07 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
81.5%
Gross profit / revenue.
Operating margin
9.6%
Operating income / revenue.
EBITDA margin
9.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-16.4%
Pre-tax income / revenue.
Net margin
-16.4%
Net income / revenue.
Operating cash flow margin
1.0%
Cash from operations / revenue.
Return on assets (ROA)
-44.7%
Net income / average total assets.
R&D / revenue
16.7%
Research and development expense / revenue.
SG&A / revenue
55.2%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
2.2%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
16.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
18.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
36.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
22.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
33.5%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
59.0%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
14.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-0.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
7.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
26.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
46.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
34.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.15x
Current assets / current liabilities.
Quick ratio
0.08x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.12
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.71
Revenue / diluted weighted shares.
Operating cash flow per share
$0.01
Cash from operations / diluted weighted shares.
Book value per share
-$1.76
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.08x
Market cap / revenue.
P/OCF
8.62x
Market cap / cash from operations, when positive.
EV/Sales
0.06x
Enterprise value / revenue.
EV/EBIT
0.59x
Enterprise value / operating income, when both are positive.
EV/EBITDA
0.59x
Enterprise value / EBITDA, when both are positive.
Earnings yield
-193.1%
Net income / market cap (the inverse of P/E).
What was BIOTRICITY INC.'s revenue in fiscal 2026?
BIOTRICITY INC. reported revenue of $16.0M for fiscal 2026, 16% higher than the year before.
Was BIOTRICITY INC. profitable in fiscal 2026?
No. It reported a net loss of $2.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.